Everolimus-Eluting versus Paclitaxel-Eluting Stents in Percutaneous Coronary Intervention: Meta-Analysis of Randomized Trials

Table 1

Description of the included trials.

Source	Number of patients		Inclusion criteria	Key exclusion criteria	Clinical follow-up duration, months
	EES	PES
Kedhi et al. [6], 2010	897	903	Consecutive patients referred for elective or emergent PCI	Planned major surgery within 30 days	24
Garg et al. [5], 2009	223	77	Ischemia and vessel size 2.5–4.25 mm and lesion length ≤28 mm	Recent MI, LVEF ≤30%, left main, heavily calcified lesion, or visible thrombus	48
Stone et al. [7], 2009	669	332	Stable, unstable angina or inducible ischemia with vessel 2.5–3.75 mm diameter and lesion length ≤28 mm	Recent MI, LVEF <30%, LM bifurcation, by-pass graft, calcification, and thrombus	36
Stone et al. [8], 2010	2458	1229	Angina or ischemia with vessel 2.5–3.75 mm diameter and lesion length ≤28 mm	Recent MI, LVEF <30%, left main bifurcation, total occlusion, heavy calcification, total occlusion, restenosis, and visible thrombus, and vein graft PCI	24

Abbreviations: EES, Everolimus-Eluting Stent; PES, Paclitaxel-Eluting Stent; MI, Myocardial Infarction; LVEF, Left Ventricular Ejection Fraction; PCI, Percutaneous Coronary Intervention.